Pharmacy Medical News about Tyrosine Kinase Inhibitor

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies
Journal of Clinical Oncology, 09/04/09

Wong C–I et al. – ABT–869 by continuous once–daily dosing was tolerable at doses <=0.25 mg/kg/d. Biomarker evidence of antiangiogenic activity and DCE–MRI evidence of tumor antiangiogenesis were observed together with promising clinical activity.

<< Previous
Early Postoperative Paclitaxel Followed by Concurrent Paclitaxel...

Next >>
Double-blind placebo-controlled study to evaluate the effect of...